Showing results (61-70 of 610) with videos related to

Sort By:
Pageof 61
Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.
Immunotherapy|July 20, 2010
New trends in epidermal growth factor receptor-directed monoclonal antibodiesBen Markman, Jaume Capdevila, Elena Elez, et al.
Gastrointestinal Cancer Research : GCR|December 17, 2009
Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancerRichard M Goldberg, Neal J Meropol, Josep Tabernero
Nature Reviews. Gastroenterology & Hepatology|November 7, 2022
Current developments in gastric cancer: from molecular profiling to treatment strategyMaria Alsina, Virginia Arrazubi, Marc Diez, et al.
Future Oncology (London, England)|November 25, 2011
Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancerLeticia De Mattos-Arruda, David Olmos, Josep Tabernero
Expert Opinion on Emerging Drugs|September 1, 2016
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancerIgnacio Matos, Elena Elez, Jaume Capdevila, et al.
Critical Reviews in Oncology/Hematology|June 14, 2014
What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?Jaume Capdevila, Alfredo Carrato, Josep Tabernero, et al.
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Personalized Medicine|August 21, 2023
Challenges and opportunities in building a health economic framework for personalized medicine in oncologyPedro Nazareth Aguiar, Silvio Matsas, Rodrigo Dienstmann, et al.
Drug Safety|December 6, 2011
Benefit-risk assessment of bevacizumab in the treatment of breast cancerRodrigo Dienstmann, Felipe Ades, Kamal S Saini, et al.
Pageof 61